Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications

Radiotherapy and Oncology

Volumn 120, Issue 2, 2016, Pages 185-194

  Popp, Ilinca ^a,b   Grosu, Anca Ligia ^a,b   Niedermann, Gabriele ^a,b   Duda, Dan G ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Abscopal effect; Checkpoint blockade; SBRT; SRS

Indexed keywords

CANCER VACCINE; CHEMOKINE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; REVIEW; STEREOTACTIC BODY RADIATION THERAPY; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES; RADIOSURGERY;

COMBINED MODALITY THERAPY; DOSE HYPOFRACTIONATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RADIOSURGERY;

EID: 84991085089     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.07.013     Document Type: Review

References (118)

1. [1] Wasserman, J., Blomgren, H., Rotstein, S., Petrini, B., Hammarström, S., Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors. Bull N Y Acad Med 65 (1989), 36–44.
2. [2] Garnett, C.T., Palena, C., Chakraborty, M., Tsang, K.Y., Schlom, J., Hodge, J.W., Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64 (2004), 7985–7994.
3. [3] Lee, Y., Auh, S.L., Wang, Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114 (2009), 589–595.
4. [4] Lugade, A.A., Sorensen, E.W., Gerber, S.A., Moran, J.P., Frelinger, J.G., Lord, E.M., Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 180 (2008), 3132–3139.
5. [5] Hennel, R., Brix, N., Seidl, K., et al. Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation. Radiat Oncol, 9, 2014, 85.
6. [6] Postow, M.A., Callahan, M.K., Barker, C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
7. [7] Golden, E.B., Demaria, S., Schiff, P.B., Chachoua, A., Formenti, S.C., An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1 (2013), 365–372.
8. [8] Gulley, J.L., Arlen, P.M., Bastian, A., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11 (2005), 3353–3362.
9. [9] Filatenkov, A., Baker, J., Mueller, A.M., et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 21 (2015), 3727–3739.
10. [10] Timmerman, R., Papiez, L., McGarry, R., et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124 (2003), 1946–1955.
11. [11] Rusthoven, K.E., Kavanagh, B.D., Burri, S.H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27 (2009), 1579–1584.
12. [12] Rusthoven, K.E., Kavanagh, B.D., Cardenes, H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27 (2009), 1572–1578.
13. [13] Chang, E.L., Shiu, A.S., Mendel, E., et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 7 (2007), 151–160.
14. [14] Zelefsky, M.J., Greco, C., Motzer, R., et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys 82 (2012), 1744–1748.
15. [15] King, C.R., Brooks, J.D., Gill, H., Presti, J.C. Jr., Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys 82 (2012), 877–882.
16. [16] Bhattacharya, I.S., Woolf, D.K., Hughes, R.J., et al. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease. Br J Radiol, 1048, 2015, 20140712.
17. [17] Guckenberger, M., Wulf, J., Mueller, G., et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 74 (2009), 47–54.
18. [18] Timmerman, R.D., Bizekis, C.S., Pass, H.I., et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin 59 (2009), 145–170.
19. [19] Mole, R.H., Whole body irradiation; radiobiology or medicine?. Br J Radiol 26 (1953), 234–241.
20. [20] Siva, S., MacManus, M.P., Martin, R.F., Martin, O.A., Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett 356 (2015), 82–90.
21. [21] Kaminski, J.M., Shinohara, E., Summers, J.B., Niermann, K.J., Morimoto, A., Brousal, J., The controversial abscopal effect. Cancer Treat Rev 31 (2005), 159–172.
22. [22] Balkwill, F.R., Capasso, M., Hagemann, T., The tumor microenvironment at a glance. J Cell Sci 125 (2012), 5591–5596.
23. [23] Haikerwal, S.J., Hagekyriakou, J., MacManus, M., Martin, O.A., Haynes, N.M., Building immunity to cancer with radiation therapy. Cancer Lett 368 (2015), 198–208.
24. [24] Dewey, W.C., Ling, C.C., Meyn, R.E., Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 33 (1995), 781–796.
25. [25] Olive, P.L., Frazer, G., Banáth, J.P., Radiation-induced apoptosis measured in TK6 human B lymphoblast cells using the comet assay. Radiat Res 136 (1993), 130–136.
26. [26] Olive, P.L., Vikse, C.M., Vanderbyl, S., Increase in the fraction of necrotic, not apoptotic, cells in SiHa xenograft tumours shortly after irradiation. Radiother Oncol 50 (1999), 113–119.
27. [27] Melcher, A., Gough, M., Todryk, S., Vile, R., Apoptosis or necrosis for tumor immunotherapy: What's in a name?. J Mol Med (Berl) 77 (1999), 824–833.
28. [28] Sauter, B., Albert, M.L., Francisco, L., Larsson, M., Somersan, S., Bhardwaj, N., Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191 (2000), 423–434.
29. [29] Todryk, S., Melcher, A.A., Hardwick, N., et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 163 (1999), 1398–1408.
30. [30] Holler, N., Zaru, R., Micheau, O., et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1 (2000), 489–495.
31. [31] French, L.E., Tschopp, J., Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 12 (2002), 51–55.
32. [32] Gasser, S., Orsulic, S., Brown, E.J., Raulet, D.H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005), 1186–1190.
33. [33] Schouppe, E., Mommer, C., Movahedi, K., et al. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events. Eur J Immunol 43 (2013), 2930–2942.
34. [34] Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23 (2002), 549–555.
35. [35] Beury, D.W., Parker, K.H., Nyandjo, M., Sinha, P., Carter, K.A., Ostrand-Rosenberg, S., Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors. J Leukoc Biol 96 (2014), 1109–1118.
36. [36] Serafini, P., Mgebroff, S., Noonan, K., Borrello, I., Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68 (2008), 5439–5449.
37. [37] Chiang, C.S., Fu, S.Y., Wang, S.C., et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol, 2, 2012, 89.
38. [38] Chen, F.H., Chiang, C.S., Wang, C.C., et al. Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors. Clin Cancer Res 15 (2009), 1721–1729.
39. [39] Burnette, B.C., Liang, H., Lee, Y., et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res 71 (2011), 2488–2496.
40. [40] Teitz-Tennenbaum, S., Li, Q., Okuyama, R., et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother 31 (2008), 345–358.
41. [41] Schmidt, A., Oberle, N., Krammer, P.H., Molecular mechanisms of treg-mediated T cell suppression. Front Immunol, 3, 2012, 51.
42. [42] Kachikwu, E.L., Iwamoto, K.S., Liao, Y.P., et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 81 (2011), 1128–1135.
43. [43] Lim, J.Y., Gerber, S.A., Murphy, S.P., Lord, E.M., Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother 63 (2014), 259–271.
44. [44] Sharabi, A.B., Nirschl, C.J., Kochel, C.M., et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3 (2015), 345–355.
45. [45] Matsumura, S., Wang, B., Kawashima, N., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181 (2008), 3099–3107.
46. [46] Ishii, N., Takahashi, T., Soroosh, P., Sugamura, K., OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv Immunol 105 (2010), 63–98.
47. [47] Maçon-Lemaître, L., Triebel, F., The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 115 (2005), 170–178.
48. [48] Zou, W., Chen, L., Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 8 (2008), 467–477.
49. [49] Zhou, Q., Munger, M.E., Veenstra, R.G., et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117 (2011), 4501–4510.
50. [50] Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., Lord, E.M., Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174 (2005), 7516–7523.
51. [51] Shiraishi, K., Ishiwata, Y., Nakagawa, K., et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res 14 (2008), 1159–1166.
52. [52] Khan, M.A., Van Dyk, J., Yeung, I.W., Hill, R.P., Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol 66 (2003), 95–102.
53. [53] Demaria, S., Ng, B., Devitt, M.L., et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58 (2004), 862–870.
54. [54] Demaria, S., Kawashima, N., Yang, A.M., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11 (2005), 728–734.
55. [55] Dewan, M.Z., Galloway, A.E., Kawashima, N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15 (2009), 5379–5388.
56. [56] Brody, J.D., Ai, W.Z., Czerwinski, D.K., et al. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol 28 (2010), 4324–4332.
57. [57] Formenti, S.C., Demaria, S., Systemic effects of local radiotherapy. Lancet Oncol 10 (2009), 718–726.
58. [58] Lissoni, P., Meregalli, S., Bonetto, E., et al. Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. J Biol Regul Homeost Agents 19 (2005), 153–158.
59. [59] Schaue, D., Ratikan, J.A., Iwamoto, K.S., McBride, W.H., Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83 (2012), 1306–1310.
60. [60] Wersäll, P.J., Blomgren, H., Pisa, P., Lax, I., Kälkner, K.M., Svedman, C., Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 45 (2006), 493–497.
61. [61] Siva, S., Callahan, J., MacManus, M.P., Martin, O., Hicks, R.J., Ball, D.L., Abscopal [corrected] effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J Thorac Oncol, 2013, e71–e72.
62. [62] Stamell, E.F., Wolchok, J.D., Gnjatic, S., Lee, N.Y., Brownell, I., The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85 (2013), 293–295.
63. [63] Ishiyama, H., Teh, B.S., Ren, H., et al. Spontaneous regression of thoracic metastases while progression of brain metastases after stereotactic radiosurgery and stereotactic body radiotherapy for metastatic renal cell carcinoma: abscopal effect prevented by the blood-brain barrier?. Clin Genitourin Cancer 10:3 (2012), 196–198.
64. [64] Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
65. [65] Rosenberg, S.A., Yang, J.C., Restifo, N.P., Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004), 909–915.
66. [66] Tivol, E.A., Borriello, F., Schweitzer, A.N., Lynch, W.P., Bluestone, J.A., Sharpe, A.H., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995), 541–547.
67. [67] Waterhouse, P., Penninger, J.M., Timms, E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995), 985–988.
68. [68] Lenschow, D.J., Walunas, T.L., Bluestone, J.A., CD28/B7 system of T cell costimulation. Annu Rev Immunol 14 (1996), 233–258.
69. [69] Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., Allison, J.P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 206 (2009), 1717–1725.
70. [70] Azuma, M., Ito, D., Yagita, H., et al. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366 (1993), 76–79.
71. [71] Qureshi, O.S., Zheng, Y., Nakamura, K., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332:6029 (2011), 600–603.
72. [72] Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
73. [73] Freeman, G.J., Long, A.J., Iwai, Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (2000), 1027–1034.
74. [74] Dong, H., Zhu, G., Tamada, K., Chen, L., B7–H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 (1999), 1365–1369.
75. [75] Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
76. [76] Latchman, Y., Wood, C.R., Chernova, T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2 (2001), 261–268.
77. [77] Francisco, L.M., Salinas, V.H., Brown, K.E., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206 (2009), 3015–3029.
78. [78] Weber, J.S., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
79. [79] Robert, C., Ribas, A., Wolchok, J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
80. [80] Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
81. [81] Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373 (2015), 123–135.
82. [82] van Elsas, A., Hurwitz, A.A., Allison, J.P., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190 (1999), 355–366.
83. [83] Li, B., Van Roey, M., Wang, C., Chen, T.H., Korman, A., Jooss, K., Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 15 (2009), 1623–1634.
84. [84] Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12 (2012), 237–251.
85. [85] Demaria, S., Bhardwaj, N., McBride, W.H., Formenti, S.C., Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63 (2005), 655–666.
86. [86] Pilones, K.A., Kawashima, N., Yang, A.M., Babb, J.S., Formenti, S.C., Demaria, S., Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res 15 (2009), 597–606.
87. [87] Twyman-Saint Victor, C., Rech, A.J., Maity, A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
88. [88] Belcaid, Z., Phallen, J.A., Zeng, J., et al. Focal radiation therapy combined with 4–1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. PLoS ONE, 9, 2014, e101764.
89. [89] Zeng, J., See, A.P., Phallen, J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 86 (2013), 343–349.
90. [90] Deng, L., Liang, H., Burnette, B., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 (2014), 687–695.
91. [91] Verbrugge, I., Hagekyriakou, J., Sharp, L.L., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 72 (2012), 3163–3174.
92. [92] Wada, S., Harris, T.J., Tryggestad, E., et al. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. Int J Radiat Oncol Biol Phys 87 (2013), 769–776.
93. [93] Yokouchi, H., Yamazaki, K., Chamoto, K., et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci 99 (2008), 361–367.
94. [94] Shi, W., Siemann, D.W., Augmented antitumor effects of radiation therapy by 4–1BB antibody (BMS-469492) treatment. Anticancer Res 26 (2006), 3445–3453.
95. [95] Honeychurch, J., Glennie, M.J., Johnson, P.W., Illidge, T.M., Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 102:4 (2003), 1449–1457.
96. [96] Hiniker, S.M., Chen, D.S., Reddy, S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5:6 (2012), 404–407.
97. [97] Crittenden, M., Kohrt, H., Levy, R., et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 25:1 (2015), 54–64.
98. [98] Slovin, S.F., Higano, C.S., Hamid, O., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 24:7 (2013), 1813–1821.
99. [99] Kwon, E.D., Drake, CG2, Scher, HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:7 (2014), 700–712.
100. [100] Chandra, R.A., Wilhite, T.J., Balboni, T.A., et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology, 4(11), 2015, e1046028.
101. [101] Patel, K.R., Shoukat, S., Oliver, D.E., et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol, 2015 [Epub ahead of print].
102. [102] Kiess, A.P., Wolchok, J.D., Barker, C.A., et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:2 (2015), 368–375.
103. [103] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:4 (2012), 252–264.
104. [104] Hoos, A., Eggermont, A.M., Janetzki, S., et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:18 (2010), 1388–1397.
105. [105] Della Vittoria Scarpati, G., Fusciello, C., Perri, F., et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther 7 (2014), 203–209.
106. [106] Brahmer, J.R., Drake, C.G., Wollner, I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:19 (2010), 3167–3175.
107. [107] Sibaud, V., David, I., Lamant, L., et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res 25:6 (2015), 555–558.
108. [108] Chi, K.H., Liu, S.J., Li, C.P., Kuo, H.P., Wang, Y.S., Chao, Y., Hsieh, S.L., Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28:2 (2005), 129–135.
109. [109] Golden, E.B., Chhabra, A., Chachoua, A., et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16:7 (2015), 795–803.
110. [110] Okwan-Duodu, D., Pollack, B.P., Lawson, D., Khan, M.K., Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol 38:1 (2015), 119–125.
111. [111] Lechleider, R.J., Arlen, P.M., Tsang, K.Y., et al. Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 14:16 (2008), 5284–5291.
112. [112] Hato, T., Goyal, L., Greten, T.F., Duda, D.G., Zhu, A.X., Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology 60:5 (2014), 1776–1782.
113. [113] Pardoll, D., Cancer and the immune system: basic concepts and targets for intervention. Semin Oncol 42:4 (2015), 523–538.
114. [114] Hong, T.S., Wo, J.Y., Yeap, B.Y., et al. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 34:5 (2016), 460–468.
115. [115] Wahl, D.R., Stenmark, M.H., Tao, Y., et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol 34:5 (2016), 452–459.
116. [116] Kozak, K.R., Kachnic, L.A., Adams, J., et al. Dosimetric feasibility of hypofractionated proton radiotherapy for neoadjuvant pancreatic cancer treatment. Int J Radiat Oncol Biol Phys 68:5 (2007), 1557–1566.
117. [117] Chakraborty, M., Abrams, S.I., Coleman, C.N., Camphausen, K., Schlom, J., Hodge, J.W., External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64 (2004), 4328–4337.
118. [118] Reits, E.A., Hodge, J.W., Herberts, C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 (2006), 1259–1271.